Company / Revenue per Share
Avalo Therapeutics, Inc. Revenue per Share History
FY2017-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Revenue per Share
$0.01
FY2025
5-year range
$0.01 / $48.96
FY2021-FY2025
Trend
-99.0%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Declined from $48.96 to $0.01 over the past 2 years.
Based on SEC 10-K filings.
0.01 in FY2025 with a 5-year CAGR of -48.2%.
Declined from $48.96 to $0.01 over the past 2 years.
Revenue per Share over time
Growth rates
- 3-Year CAGR
- -85.7%
- 5-Year CAGR
- -48.2%
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, revenue per share decreased 99.0% year-over-year.
- Peak revenue per share was recorded in FY2023.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -3.59 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Revenue per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $0.01 | -99.0% |
| FY2024 | $0.55 | -98.9% |
| FY2023 | $48.96 | +2449.7% |
| FY2022 | $1.92 | +2568.4% |
| FY2021 | $0.07 | -52.3% |
| FY2020 | $0.15 | -8.8% |
| FY2019 | $0.17 | -26.4% |
| FY2018 | $0.22 | -92.4% |
| FY2017 | $2.95 | - |
As of FY2025 · SEC Form 10-K · Last checked Jun 21, 2026